Nikhil C. Munshi, MD
Adjunct Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Hematology & Medical Oncology

MBBS, Maharaja Sayajirao University
MD, Maharaja Sayajirao University

Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.

VA Boston Healthcare System

Integrative Oncogenomics of Multiple Myeloma

SPORE in Multiple Myeloma

Molecular Manipulation to Enhance Anti-Myeloma Response

Yr Title Project-Sub Proj Pubs
2023 Molecular Manipulation to Enhance Anti-Myeloma Response 2I01BX001584-09
2022 Tissue Banking Core 5P50CA100707-19-8564
2022 SPORE in Multiple Myeloma 5P50CA100707-19
2022 Targeting AP Nuclease, a Mediator of Genomic Instability in MM 5P50CA100707-19-8567
2021 Molecular Manipulation to Enhance Anti-Myeloma Response 5I01BX001584-08 40
2021 Project 4. Targeting genomic instability and evolution in myeloma 5P01CA155258-10-5947 229
2021 Core 1: Administrative and Communication Core 5P01CA155258-10-5939 229
2021 Integrative Oncogenomics of Multiple Myeloma 5P01CA155258-10 229
2021 Targeting AP Nuclease, a Mediator of Genomic Instability in MM 5P50CA100707-18-8567 422
2021 Tissue Banking Core 5P50CA100707-18-8564 422
Showing 10 of 89 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC. Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma. Blood. 2023 May 25; 141(21):2599-2614. PMID: 36630605
  2. Samur MK, Szalat R, Munshi NC. Single-Cell Profiling in Multiple Myeloma: Insights, Problems, and Promises. Blood. 2023 May 17.View Related Profiles. PMID: 37196627
  3. Kumar S, Zhao J, Talluri S, Buon L, Mu S, Potluri B, Liao C, Shi J, Chakraborty C, Gonzalez GB, Tai YT, Patel J, Pal J, Mashimo H, Samur MK, Munshi NC, Shammas MA. Elevated APE1 dysregulates homologous recombination and cell cycle driving genomic evolution, tumorigenesis and chemoresistance in esophageal adenocarcinoma. Gastroenterology. 2023 May 11.View Related Profiles. PMID: 37178737
  4. Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023 Apr 06; 141(14):1724-1736.View Related Profiles. PMID: 36603186
  5. Delforge M, Otero PR, Shah N, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Devlen J, Miera M, Gerould H, Campbell TB, Munshi NC. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial. Leuk Res. 2023 Jun; 129:107074. PMID: 37087950
  6. Stong N, Ortiz-Estévez M, Towfic F, Samur M, Agarwal A, Corre J, Flynt E, Munshi N, Avet-Loiseau H, Thakurta A. The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood. 2023 Mar 30; 141(13):1574-1583. PMID: 35984902
  7. Tam CS, Kapoor P, Castillo JJ, Buske C, Ansell SM, Branagan AR, Kimby E, Li Y, Palomba ML, Qiu L, Shadman M, Abeykoon JP, Sarosiek S, Vos J, Yi S, Stephens D, Roos-Weil D, Roccaro AM, Morel P, Munshi NC, Anderson KC, San-Miguel J, Garcia-Sanz R, Dimopoulos MA, Treon SP, Kersten MJ. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials. Semin Hematol. 2023 Mar 24. PMID: 37099031
  8. Merz M, Hu Q, Merz AMA, Wang J, Hutson N, Rondeau C, Celotto K, Belal A, Alberico R, Block AW, Mohammadpour H, Wallace PK, Tario J, Luce J, Glenn ST, Singh P, Samur M, Munshi N, Liu S, McCarthy PL, Wei L, Hillengass J. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma. Blood Adv. 2023 Mar 14; 7(5):718-733. PMID: 35868022; PMCID: PMC9984963; DOI: 10.1182/bloodadvances.2022007457;
  9. Yao Y, Fong Ng J, Park WD, Samur MK, Morelli E, Encinas J, Chyra Z, Xu Y, Derebail S, Epstein CB, Nabet B, Chesi M, Gray NS, Young R, Kwiatkowski N, Mitsiades CS, Anderson KC, Lin CY, Munshi NC, Fulciniti M. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 2023 Mar 06. PMID: 36877894
  10. Edwards CV, Hassan H, Yildirim C, Ferri G, Verma KP, Murray Horwitz ME, Fillmore NR, Munshi NC. Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma. Blood Adv. 2023 Feb 28; 7(4):482-490.View Related Profiles. PMID: 36409606; PMCID: PMC9979755; DOI: 10.1182/bloodadvances.2022008021;
Showing 10 of 561 results. Show More